Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

2.9K
The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
2.9K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interstitial loss of heterozygosity at Chr19q13 in CD33-negative AML.

Leukemia·2026
Same author

Catching a chameleon.

Science (New York, N.Y.)·2026
Same author

Genomic landscape and precision therapy in prostate cancer: current status and future directions.

NPJ precision oncology·2026
Same author

<i>BRCA2</i> and <i>NF2</i>-Mutated High-Grade Renal Cell Carcinoma: A Case Report and Literature Review.

International journal of surgical pathology·2026
Same author

Consensus recommendations in the management of jaw (gnathic) osteosarcoma.

Cancer·2026
Same author

cellMCD Effectively Discovers Drug Resistance and Sensitivity Genes for Acute Myeloid Leukemia.

Genes·2026
Same journal

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma.

Molecular oncology·2026
Same journal

From tumor-centric to ecosystem-based hypotheses in brain tumor research and care: Proceedings from The second Brain Tumor Meeting by the Sea organized by Julie Gavard and Eric Chevet, held in St Malo (France), 23-25 March 2026.

Molecular oncology·2026
Same journal

Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.

Molecular oncology·2026
Same journal

In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.

Molecular oncology·2026
Same journal

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

Molecular oncology·2026
Same journal

EXPRESSION OF CONCERN: A Newly Identified 45-kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance.

Molecular oncology·2026
See all related articles

Related Experiment Video

Updated: May 22, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K

Revisiting CDKN2A dysregulation in Ewing sarcoma.

Anjali Paragji1, Vivek Shastri1, Elham Nasri2

  • 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, The University of Florida, Jacksonville, FL, USA.

Molecular Oncology
|March 13, 2025
PubMed
Summary
This summary is machine-generated.

High expression of CDKN2A is a negative prognostic biomarker in Ewing sarcoma (EwS) patients at diagnosis. This finding suggests CDKN2A

Keywords:
biomarkernext‐generation sequencingprognosis

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.2K

Related Experiment Videos

Last Updated: May 22, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K
Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.2K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Ewing sarcoma (EwS) is a rare, aggressive pediatric cancer.
  • Genomic copy number deletion of CDKN2A is a common variant in EwS.
  • The clinical significance of CDKN2A dysregulation in EwS remains unclear.

Purpose of the Study:

  • To investigate the role of CDKN2A as a prognostic biomarker in EwS.
  • To explore the functional impact of CDKN2A dysregulation in EwS.
  • To assess the association between CDKN2A expression and patient outcomes.

Main Methods:

  • Analysis of pre-clinical EwS models and clinical patient samples.
  • Evaluation of CDKN2A expression levels and copy number.
  • Assessment of downstream CDK4/CCND1 activity.

Main Results:

  • CDKN2A dysregulation may be essential in EwS pathogenesis.
  • Sustained CDK4/CCND1 activity is linked to CDKN2A dysregulation.
  • High CDKN2A expression is a negative prognostic biomarker in three independent EwS datasets.

Conclusions:

  • High CDKN2A expression at diagnosis indicates a poor prognosis in EwS.
  • CDKN2A's role may vary depending on the clinical context of EwS.
  • Further research is needed to fully validate CDKN2A's function in EwS.